Welcome to our dedicated page for BioAtla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on BioAtla stock.
BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biopharmaceutical company committed to advancing the treatment of cancer through its innovative protein therapeutic products. Headquartered in San Diego, California, with a strategic presence in Beijing, China, BioAtla leverages its proprietary Conditionally Active Biologics (CAB) technology to develop novel monoclonal and bispecific antibodies.
The core of BioAtla's work lies in the engineering of antibodies that become active under the unique conditions of the tumor microenvironment, thus improving tumor selectivity and reducing on-target toxicity. This technology aims to enhance the therapeutic index of drug candidates, ultimately providing safer and more effective cancer treatments.
BioAtla's pipeline includes several promising candidates. Mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) are in Phase 2 clinical testing, targeting AXL and ROR2 respectively. Another key asset, evalstotug (BA3071), is a CTLA-4 inhibitor designed to minimize systemic toxicity and facilitate safer combination therapies with anti-PD-1 antibodies. Furthermore, the company's first bispecific T-cell engager antibody, BA3182, is undergoing Phase 1 trials, focusing on EpCAM and engaging CD3 expressing T cells.
BioAtla has an extensive patent portfolio, with over 750 patents filed, more than 475 of which have been granted. This robust intellectual property coverage supports the company's competitive edge in the biotechnology sector.
Recent updates include the initiation of a Phase 1 clinical trial for BA3361, a next-generation CAB-Nectin4-ADC, which demonstrated superior activity in pancreatic cancer models. The company also continues to build strategic partnerships and collaborations to advance its research and commercialize its products effectively.
For further information and the latest updates, visit BioAtla's official website or contact their investor relations team.
BioAtla (Nasdaq: BCAB) hosted a virtual R&D Day highlighting updates on its clinical programs. Key findings include:
1. Mecbotamab vedotin (CAB-AXL-ADC): Showed clinical benefit in NSCLC patients with mutant KRAS variants. AXL expression ≥1% correlated with clinical benefit in heavily pretreated patients.
2. Evalstotug (CAB-CTLA-4 antibody): Demonstrated promising anti-tumor activity as monotherapy and in combination with PD-1, with a differentiated safety profile and low incidence of immune-related adverse events.
The event featured insights from key opinion leaders Dr. Edwin Yau, Dr. Omid Hamid, and Dr. Ankit Mangla, who shared positive observations on the clinical benefits and safety profiles of BioAtla's therapies.
BioAtla (Nasdaq: BCAB) has received FDA Fast Track Designation for ozuriftamab vedotin (CAB-ROR2-ADC) to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). This conditionally active antibody drug conjugate has shown promising clinical activity and a manageable safety profile in treatment-refractory SCCHN patients during its Phase 2 trial. The company plans to meet with the FDA in the second half of 2024 to discuss a potential registrational trial. Fast Track Designation could expedite development and review, potentially leading to priority review if supported by clinical data at BLA submission.
BioAtla, a global clinical-stage biotechnology company specializing in CAB antibody therapeutics for solid tumors, will host a virtual R&D Day on July 25, 2024, at 10:00 AM ET. This event will provide updates on the company's clinical programs and pipeline. Attendees can register online, and a live Q&A session will follow the presentation.
BioAtla (Nasdaq: BCAB), a clinical-stage biotech firm specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, announced its participation in the Jefferies Global Healthcare Conference in New York from June 4-6, 2024.
The event will feature a fireside chat and one-on-one investor meetings on June 5, 2024, at 8:00 a.m. ET. The webcast will be available for interested parties.
BioAtla announced promising Phase 1 clinical trial results for evalstotug, a conditionally active anti-CTLA-4 antibody, in combination with nivolumab.
Key findings include prolonged progression-free survival (PFS) of over 10 months in refractory PD1 failure patients, with manageable safety profiles allowing extended treatment durations.
High doses (up to 1 gram) showed positive responses, including complete and partial responses in various carcinomas. The disease control rate was 52%, and several patients remained progression-free for over a year.
BioAtla plans to commence a Phase 3 trial in late 2024 for first-line metastatic BRAF-mutated melanoma, following an anticipated FDA meeting.
BioAtla (Nasdaq: BCAB) announced its Q1 2024 financial results and clinical progress. Key highlights include positive Phase 2 data for ozuriftamab vedotin in SCCHN, with 11 responses and an 86% Disease Control Rate (DCR). Evalstotug's Phase 1 study shows promising safety and efficacy, with upcoming Phase 2 data readouts. Mecbotamab vedotin's Phase 2 trial in UPS is progressing well. BioAtla also reported a cash balance of $80.6 million, projected to fund operations into 2H 2025. Financial results show a reduction in R&D and G&A expenses but a net loss of $23.2 million, lower than last year's $27.5 million. Management will host a conference call to discuss these updates.
BioAtla, Inc. (Nasdaq: BCAB) will be participating in the Citizens JMP Life Sciences Conference in New York on May 13-14, 2024. The company focuses on developing CAB antibody therapeutics for solid tumor treatment. Management will engage in a fireside chat and investor meetings. This conference provides a platform for BioAtla to showcase its advancements.
BioAtla, Inc. (Nasdaq: BCAB) will host a conference call and webcast on May 14, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and provide business highlights. The company focuses on developing CAB antibody therapeutics for solid tumors.
BioAtla, Inc. (Nasdaq: BCAB) received FDA clearance for its investigational new drug BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for treating various tumors. The CAB technology aims to reduce toxicities, and recent data at the AACR Annual Meeting showcased improved serum stability and potency. BA3361 showed complete tumor regression in cell line xenograft models, superior efficacy in pancreatic cancer, and reduced toxicity. This marks BioAtla's advancement in developing innovative cancer treatments.
FAQ
What is the current stock price of BioAtla (BCAB)?
What is the market cap of BioAtla (BCAB)?
What is BioAtla, Inc. known for?
Where are BioAtla's main operations located?
What are BioAtla's leading drug candidates?
What is CAB technology?
How extensive is BioAtla's patent portfolio?
What recent developments has BioAtla announced?
Who can I contact for more information about BioAtla?
What types of cancers are BioAtla's treatments targeting?
What are the benefits of BioAtla's CAB technology?
Where can I find BioAtla's latest news and updates?
